SSE-Bio: A Structured Self-Evolving Agent with Agentic Retrieval Policy for Multi-Hop Biomedical Reasoning
Organizations: School of Computing Science, University of Glasgow · Brigham and Women’s Hospital, Harvard Medical School, Harvard University · Language Technology Lab, University of Cambridge · School of Natural and Computing Science, University of Aberdeen ·
Abstract
Biomedical multi-hop question answering (QA) requires models to connect evidence across intermediate entities such as diseases, drugs, proteins, and phenotypes. Existing agents typically rely on static retrieval workflows or coarse-grained prompt rewriting, which can lead to instruction drift when reasoning procedures need to be updated. We propose SSE-Bio, a structured self-evolving agent with an agentic retrieval policy for multi-hop biomedical reasoning. Instead of globally rewriting agent instructions, SSE-Bio maintains a structured state, selectively retrieves knowledge triplets and prior templates through a trainable proxy policy, and improves its reasoning memory through fine-grained template editing. To optimise retrieval decisions, we introduce a proxy-training strategy based on group relative policy optimization, where the proxy is improved through decision-contrastive groups over alternative retrieval choices. Experiments on three biomedical multi-hop QA benchmarks show that SSE-Bio consistently outperforms existing baselines, achieving an improvement of 6.56 absolute points over the strongest self-evolving baseline on BioHopR.
Figures & tables
| Family | Method | Single Answer | Multi Answer | ||||||
| Prec H1 | Prec H2 | Both cor | Both wr | Prec H1 | Prec H2 | Both cor | Both wr | ||
| LLM | Llama-3.1-8B | 0.13 | 0.04 | 0.00 | 99.83 | 0.07 | 0.01 | 0.00 | 99.92 |
| LLM | Llama-3.1-70B | 26.41 | 9.45 | 4.94 | 69.06 | 19.82 | 6.94 | 3.24 | 76.51 |
| LLM | GPT-4o | 32.86 | 14.59 | 7.84 | 60.43 | 25.48 | 10.71 | 5.25 | 69.03 |
| Medical LLM | HuatuoGPT-70B | 0.15 | 0.00 | 0.00 | 99.84 | 0.09 | 0.00 | 0.00 | 99.91 |
| Medical LLM | HuatuoGPT-8B | 0.21 | 0.03 | 0.00 | 99.76 | 0.11 | 0.01 | 0.00 | 99.88 |
| Model / Setting | Backbone | Single Answer | Multi Answer | ||||||
| Prec H1 | Prec H2 | Both cor | Both wr | Prec H1 | Prec H2 | Both cor | Both wr | ||
| Effect of Structured State Tracking and Fine-grained Template Evolution | |||||||||
| Free-form state + rewriting | Qwen-72B | 41.58 | 16.93 | 11.72 | 53.21 | 32.94 | 12.58 | 8.04 | 62.52 |
| Structured state + rewriting | Qwen-72B | 44.12 | 18.92 | 13.86 | 50.82 | 35.07 | 14.18 | 9.66 | 60.41 |
| Free-form state + editing | Qwen-72B | 45.03 | 19.47 | 14.52 | 50.02 | 35.88 | 14.86 | 10.28 | 59.54 |
| Structured state + editing | Qwen-72B | 47.21 | 21.38 | 16.52 | 47.93 | 38.36 | 16.24 | 11.73 | 57.13 |
| Relation Type | STELLA | SSE-Bio | ||||||
| Single Answer | Multi Answer | Single Answer | Multi Answer | |||||
| Prec H1 | Prec H2 | Prec H1 | Prec H2 | Prec H1 | Prec H2 | Prec H1 | Prec H2 | |
| Same Query and Bridge | ||||||||
| Disease:Drug:Phenotype | 48.27 | 22.83 | 38.64 | 10.58 | 59.12 † | 34.26 † | 47.03 † | 16.82 † |
| Disease:Drug:Protein | 46.75 | 10.36 | 37.42 | 4.37 | 52.18 † | 12.41 † | 41.02 † | 5.06 † |
| Drug:Disease:Phenotype | 50.18 | 20.67 | 33.15 | 8.74 | 58.74 † | 27.35 † | 37.91 † | 11.96 † |
Appendix figures & tables19 assets
Supplementary material from the paper’s appendix.
Appendix
| Memory | Field | Role |
| State | Task type | template retrieval query |
| State | Information gap | triplet retrieval query |
| State | Feedback | Critic guidance for refinement |
| State | Retrieval state | retrieved evidence summary |
| Template | Task type | template retrieval key |
| Template | Reasoning flow | reusable reasoning steps |
| System Prompt | Single Answer | Multi Answer | ||||||
| Prec H1 | Prec H2 | Both cor | Both wr | Prec H1 | Prec H2 | Both cor | Both wr | |
| Empty | 46.38 | 20.71 | 16.08 | 48.62 | 37.64 | 15.61 | 11.21 | 58.04 |
| Basic | 46.72 | 20.96 | 16.27 | 48.31 | 37.91 | 15.87 | 11.44 | 57.68 |
| SSE-Bio | 47.21 | 21.38 | 16.52 | 47.93 | 38.36 | 16.24 | 11.73 | 57.13 |
| Manager / Critic | Dev | Single Answer | Multi Answer | ||||||
| Prec H1 | Prec H2 | Both cor | Both wr | Prec H1 | Prec H2 | Both cor | Both wr | ||
| Gemini-2.5-Pro | Claude-4.5-Sonnet | 47.21 | 21.38 | 16.52 | 47.93 | 38.36 | 16.24 | 11.73 | 57.13 |
| Gemini-2.5-Flash | Claude-4.5-Sonnet | 45.96 | 20.14 | 15.86 | 49.08 | 37.02 | 15.12 | 11.04 | 58.36 |
| GPT-5.5 | Claude-4.5-Sonnet | 46.54 | 20.83 | 16.11 | 48.57 | 37.68 | 15.74 | 11.38 | 57.91 |
| GPT-5.5-Mini | Claude-4.5-Sonnet | 45.31 | 19.62 | 15.42 | 49.74 | 36.44 | 14.83 | 10.72 | 58.92 |
| Model | Tokens (M) | Both cor |
| Biomni | 23.6 | 10.45 |
| STELLA | 21.2 | 9.96 |
| SSE-Bio | 28.3 | 16.52 |
| Method | Tokens / Ex. | LLM Calls / Ex. | Latency / Ex. | API Cost / Ex. |
| Biomni | 10.3K | 5.8 | 18.4s | $0.039 |
| STELLA | 9.3K | 4.9 | 16.7s | $0.035 |
| SSE-Bio | 12.4K | 6.7 | 22.1s | $0.047 |
| Stage | Tokens | Data / Rollouts | GPU-h |
| Proxy SFT | 41.6M | 12.6K labelled pairs | 42 |
| Proxy GRPO | 132.4M | 38.5K rollouts | 96 |
| Hyperparameter | Value |
| Proxy backbone | Qwen-2.5-72B |
| SFT learning rate | |
| SFT batch size | 64 |
| SFT max length | 2048 |
| SFT # epochs | 1 |
| GRPO learning rate |
| Statistic | Value | Interpretation |
| Initial persistent templates | 0 | The memory starts empty; no held-out BioHopR, MedHop, or HLE examples are used to seed templates. |
| Accepted post-success updates | 2.47K | Training-only updates accepted after successful trajectories and critic validation. |
| New-template distillations | 612 | Updates whose task type does not align with an existing template above . |
| Fine-grained edit operations | 1.86K | Updates applied to aligned templates without changing the task type. |
| Final deduplicated templates | 512 | Compact memory checkpoint used for all held-out evaluations. |
| Covered task types | 24 | Twelve BioHopR relation schemas under single-answer and multi-answer variants. |
| Step type | Supported if | Not supported if |
| Bridge resolution | A retrieved triplet or accepted template step links the query entity to the proposed bridge with the required relation type. | The bridge is introduced only from parametric generation or by a triplet with an incompatible schema. |
| Answer verification | The final answer is linked to the resolved bridge by a retrieved triplet, or satisfies the retrieved template’s verification criteria. | The answer is plausible but lacks explicit bridge-to-answer evidence. |
| Multi-answer coverage | Every returned entity has support, and the state records that candidate expansion has been exhausted within the retrieval budget. | The trajectory stops after finding only one supported entity when the task type requires a set. |
| No-retrieval branch | The existing retrieval state already contains the evidence needed by the current plan. | The branch avoids retrieval while the information gap remains unresolved. |
| Statistic | Value | Interpretation |
| BioHopR training pairs | 5.34K | Training split used for trajectory construction and persistent template-memory updates. |
| Candidate rollouts before pruning | 82.4K | Mean 15.4 rollouts per pair, close to the upper bound from expanding the first two retrieval decisions. |
| Valid parsed rollouts | 76.8K | 93.2% of generated rollouts have valid state, action, evidence, and answer fields. |
| Evidence-bearing non-duplicate rollouts | 49.7K | Remaining rollouts after removing duplicate state-action paths and branches with empty selected evidence. |
| Retained GRPO rollouts | 38.5K | Mean group size after the cap; median group size is 8.0. |
| Discarded or pruned rollouts | 43.9K | 53.3% of generated rollouts are removed by parsing, duplicate/evidence filters, or the group-size cap. |
| Retrieval Policy | Single Answer | Multi Answer | ||||||
| Prec H1 | Prec H2 | Both cor | Both wr | Prec H1 | Prec H2 | Both cor | Both wr | |
| Retrieve neither | 39.74 | 15.88 | 10.62 | 55.00 | 30.81 | 11.92 | 7.05 | 64.32 |
| Retrieve KG only | 42.36 | 17.41 | 12.43 | 52.84 | 33.18 | 13.06 | 8.52 | 62.37 |
| Retrieve template only | 41.58 | 16.96 | 11.86 | 53.46 | 32.47 | 12.64 | 8.07 | 62.98 |
| Retrieve KG + template | 43.27 | 18.12 | 13.18 | 51.76 | 34.02 | 13.58 | 9.02 | 61.31 |
| Learned Proxy | 47.21 | 21.38 | 16.52 | 47.93 | 38.36 | 16.24 | 11.73 | 57.13 |
| Setting | Single Answer | Multi Answer | ||||||
| Prec H1 | Prec H2 | Both cor | Both wr | Prec H1 | Prec H2 | Both cor | Both wr | |
| Top-5 retrieved triplets | 47.21 | 21.38 | 16.52 | 47.93 | 38.36 | 16.24 | 11.73 | 57.13 |
| + 2 random noisy triplets | 46.32 | 20.76 | 16.02 | 48.64 | 37.58 | 15.68 | 11.31 | 57.86 |
| Metric | Coarse rewriting | Fine-grained editing |
| Changed fields / update | 3.28 | 1.46 |
| Unchanged-field preservation | 64.0 | 88.0 |
| Unsupported new instruction | 12.0 | 4.0 |
| Contradictory instruction | 7.0 | 2.0 |
| Error Source | Share (%) |
| Dev reasoning error | 31.2 |
| Triplet retrieval failure | 24.6 |
| Wrong Proxy action | 13.1 |
| Answer-format / coverage error | 11.4 |
| Template mismatch | 10.8 |
| Critic feedback error | 8.9 |
| Item | STELLA | SSE-Bio |
| Question pattern | Drug Gene/Protein Disease | Drug Gene/Protein Disease |
| Question | Name a disease that is related to a gene/protein that is associated with drug (2S)-2-{[HYDROXY(4-IODOBENZYL)PHOSPHORYL]METHYL}PENTANEDIOIC ACID. | |
| Gold bridge | FOLH1 | |
| Gold answer | {neurotic disorder, colorectal neoplasm, prostate cancer, schizophrenia, dysthymic disorder, colorectal cancer, familial prostate carcinoma, colorectal carcinoma, unipolar depression, anxiety disorder, prostate carcinoma} | |
| Predicted bridge | AR | FOLH1 |
| Retrieved evidence | Retrieves disease-associated context around prostate cancer and androgen-receptor signalling, but does not establish that the query drug is associated with AR. | Retrieves relation-specific triplets supporting both hops: ((2S)-2-PENTANEDIOIC ACID, associated with, FOLH1) and (FOLH1, related to, prostate cancer) . |
Biomedical QA
Biomedical question answering develops systems that answer health and life-science questions using clinical knowledge, research literature, and structured data.
See all 51 papers